Researchers describe protease inhibitor that may aid in diabetic retinopathy treatment
Wednesday, January 21, 2009 - 13:15
in Health & Medicine
Researchers from Joslin Diabetes Center, Boston, and ActiveSite Pharmaceuticals, Inc., San Francisco, announced today that they have demonstrated that a specific inhibitor of the protease plasma kallikrein, ASP-440, developed by ActiveSite Pharmaceuticals, may provide a new therapeutic approach for treatment of diabetic retinopathy, the most common eye-related complication of diabetes. The study, which was partly funded by the Juvenile Diabetes Research Foundation (JDRF), is published in the February 2009 issue of the journal Hypertension.
Read the whole article on Physorg
More from Physorg
Related
- Researchers describe protease inhibitor that may aid in diabetic retinopathy treatmentWed, 21 Jan 2009, 13:18:06 EST
- JDRF funded research shows promise for prevention, reversal of type 1 diabetesTue, 18 Nov 2008, 14:52:22 EST
- JDRF funded study links 'hygiene hypothesis' to diabetes preventionMon, 6 Oct 2008, 16:14:36 EDT
- Ophthalmology highlights Jan. 2009Mon, 5 Jan 2009, 13:36:18 EST
- Science, hope for adults with type 1 diabetes focus of JDRF's Annual Global Diabetes Research ForumWed, 18 Jun 2008, 17:35:24 EDT